TickerFacts.

Company research / BMY

Bristol Myers Squibb Co (BMY)

Also trades as CELG-RI. Every security a company lists rests on one set of financial statements, so these figures cover the whole company.

Build a valuation ↗↓ Download CSV

SEC name BRISTOL MYERS SQUIBB CO · CIK 0000014272 · NYSE · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Bristol Myers Squibb Co reported revenue of $48.19B. Revenue fell 0.2% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $49.19B.

Key ratios (year ended 2025-12-31)

14.6%
Net margin
38.2%
Return on year-end equity
-0.2%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-10-05

Headquarters locality: New York City · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312020-09-302020-06-302020-03-312019-12-31
Revenue$49.19B$48.19B$48.30B$45.01B$46.16B$46.38B$42.52Bn/an/an/a$26.14B
Cost of Revenue$14.68B$13.94B$13.97B$10.69B$10.14B$9.94B$11.77Bn/an/an/a$8.08B
Gross Profit$34.51Bn/an/an/an/an/a$30.75Bn/an/an/a$18.07B
R&D Expense$10.72B$9.95B$11.16B$9.30B$9.51B$10.20B$10.05Bn/an/an/a$6.15B
Depreciation & Amortization$3.18B$4.01B$9.60B$9.76B$10.28B$10.69B$10.38Bn/an/an/a$1.75B
Net Income$9.28B$7.05B-$8.95B$8.03B$6.33B$6.99B-$9.02Bn/an/an/a$3.44B
EPS (Diluted)n/a$3.46-$4.41$3.86$2.95$3.12-$3.99n/an/an/a$2.01
Total Assets$87.63B$90.04B$92.60B$95.16B$96.82B$109.31B$118.48B$125.54B$128.08B$129.28B$129.94B
Total Liabilities$65.31B$71.53B$76.22B$65.67B$65.70B$73.31B$80.60Bn/an/an/a$78.25B
Long-Term Debt$42.86B$44.83B$49.43B$39.53B$38.95B$44.37B$50.34B$44.61B$46.11B$46.10B$46.15B
Shareholders' Equity$22.32B$18.47B$16.34B$29.43B$31.06B$35.95B$37.82Bn/an/an/a$51.60B
Cash & Equivalents$8.72B$10.21B$10.35B$11.46B$9.12B$13.98B$14.55B$19.43B$19.93B$15.82B$12.35B
Operating Cash Flow$12.78B$14.16B$15.19B$13.86B$13.07B$16.21B$14.05Bn/an/an/a$8.21B
Capital Expenditures$1.34B$1.31B$1.25B$1.21B$1.12B$973.00M$753.00Mn/an/an/a$836.00M
Free Cash Flow$11.44B$12.85B$13.94B$12.65B$11.95B$15.23B$13.30Bn/an/an/a$7.37B
Share Repurchasesn/a$0$0$5.16B$8.00B$6.29B$1.55Bn/an/an/a$7.30B
Dividends Paid$5.09B$5.04B$4.86B$4.74B$4.63B$4.40B$4.08Bn/an/an/a$2.68B
Dividends Per Sharen/a$2.49$2.42$2.31$2.19$2.01$1.84n/an/an/a$1.68
Weighted Average Diluted Sharesn/a2.04B2.03B2.08B2.15B2.25B2.26Bn/an/an/a1.71B
EPS (Basic)n/a$3.47-$4.41$3.88$2.97$3.15-$3.99n/an/an/a$2.02

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView